• Report Adverse Event or Product Quality Complaint
  • Global Site
AstraZeneca Medical Information
  • Prescribing Information
  • Resources
    • Congress Library
    • Our Pipeline
    • AZ Clinical Trials
    • Externally Sponsored Scientific Research
  • Connect
    • Send MIR
    • Give Feedback

Search Medical Information

European Lung Cancer Congress - ELCC

March 26 - 29, 2025

  1. Datopotamab Deruxtecan
  2. Durvalumab
  3. Osimertinib
  4. Savolitinib
  5. Savolitinib Osimertinib
  6. Datopotamab Deruxtecan Osimertinib
  7. Datopotamab Deruxtecan Rilvegostomig
  8. Trastuzumab Deruxtecan Rilvegostomig

pdf

Effects of Datopotamab deruxtecan (Dato-DXd) vs. docetaxel on patient-reported outcomes (PROs) in adults with previously treated advanced or metastatic non squamous (NSQ) non-small cell lung cancer (NSCLC): results from TROPION-LUNG01

pdf

Association of TROP2 quantitative continuous scoring (QCS) normalised membrane ratio (NMR) with efficacy in Chinese patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC) treated with datopotamab deruxtecan (Dato-DXd) in TROPION-PanTumor02.

pdf

Patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC (AEGEAN)

pdf

Sites of relapse and subsequent therapy in the BR.31 phase 3 study of durvalumab vs placebo in resected stage IB-IIIA NSCLC

pdf

Global qualitative assessment of factors affecting multidisciplinary team (MDT) care in early-stage NSCLC

pdf

An international multicentre open-label randomised phase III trial evaluating the benefit of adding adjuvant durvalumab after neoadjuvant chemo-immunotherapy in stage IIB-IIIB (N2) resectable NSCLC

pdf

Real-world 5-year survival outcomes with durvalumab (D) after chemoradiotherapy (CRT) in unresectable, stage III NSCLC (urNSCLC): final data extraction from PACIFIC-R

pdf

Durvalumab (D) as consolidation therapy for limited-stage small-cell lung cancer (LS-SCLC): ADRIATIC China subgroup analysis

pdf

First-line (1L) durvalumab (D) + platinum-etoposide (EP) in extensive-stage SCLC (ES-SCLC): Final results and exploratory biomarker analyses from LUMINANCE

ppt

Patient-reported outcomes (PROs) from the LAURA study: osimertinib (osi) in patients (pts) with unresectable (UR) EGFR-mutated (EGFRm) stage (stg) III NSCLC without progression after definitive chemoradiation (CRT)

pdf

Long-term survival outcomes with first line (1L) osimertinib monotherapy treatment in U.S. patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations

pdf

Characterisation of benefit-risk by pemetrexed (pem) exposure in patients (pts) with EGFRm aNSCLC treated with 1L osimertinib (osi) + platinum-pem in FLAURA2

pdf

Real-world patterns of patients with disease progression after first-line osimertinib for EGFRm aNSCLC in China (FLOURISH study)

pdf

Final overall survival and long-term safety outcomes of savolitinib in patients with locally advanced or metastatic NSCLC harboring MET exon 14 (METex14) mutation: An update from a Phase 3b study

ppt

SAVANNAH: Savolitinib (savo) + osimertinib (osi) in patients (pts) with EGFRm advanced NSCLC and MET overexpression (OverExp) and/or amplification (AMP) following progressive disease (PD) on osi

ppt

Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD

pdf

TROPION-Lung14: A Phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR-mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).

pdf

TROPION-Lung15: A Phase 3 study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib.

PDF

TROPION-Lung10: Phase 3 study of datopotamab deruxtecan (Dato-DXd) + rilvegostomig for non-squamous (NSQ) advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with high PD-L1 expression and without actionable genomic alterations (AGAs)

pdf

Phase 1b open-label study of trastuzumab deruxtecan (T-DXd) + rilvegostomig ± carboplatin as first-line treatment for metastatic HER2-overexpressing (HER2-OE) non-small cell lung cancer (NSCLC): DESTINY-Lung03 Part 4

Need Help?

Contact Us

Send MIR

Submit a Medical Information Request

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

AstraZeneca Logo

This platform is provided as service to healthcare professionals by AstraZeneca Philippines, for medical educational purposes only.

©2024 AstraZeneca. All rights reserved.

PH-10554.

Last Updated 5/24

Contact Us

About Us

AstraZeneca.com

Survey Feedback

Privacy Notice

Legal Notice

Cookie Notice

Global Site

Report Adverse Event or Product Quality Complaint

Privacy NoticeLegal NoticeCookie Notice

Welcome to AstraZeneca Philippines Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the Philippines, for medical educational purposes only. AstraZeneca does not engage in the promotion of unregistered products or unapproved indications. The dissemination of this information may be subject to different medical and regulatory requirements in other countries

Are you a healthcare professional practicing in the Philippines?

No